Low expression of miR-381 is a favorite prognosis factor and enhances the chemosensitivity of osteosarcoma.
Osteosarcoma (OS) is the most common primary bone malignancy with a poor prognosis for all races and both sexes. In this study, we found that miR-381 is a positive prognosis factor for OS patients that OS patients with a low expression of miR-381 had a longer survival time after surgical intervention, and miR-381 expression promotes MG-63 cell proliferation and cell invasion ability. Our results also showed a strong negative correlation between the expression of miR-381 and LRRC4 (brain relative specific expression gene) in OS tissues. This demonstrated that LRRC4 is a direct target gene of miR-381, and suppressing the expression of miR-381 increases the sensitivity of OS cells to chemotherapeutic drugs through the LRRC4-mediated mTOR pathway. In summary, miR-381 is an important biomarker in directing therapeutic intervention and predicting prognosis in OS patients.
Department of Spinal Surgery, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Yunchao
Y
Li
Cancer Research Institute, School of Basic Medical Science, Central South University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Key Laboratory of Carcinogenesis, Ministry of Health, Changsha, Hunan, China.
Chunhua
C
Zhao
Cancer Research Institute, School of Basic Medical Science, Central South University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Key Laboratory of Carcinogenesis, Ministry of Health, Changsha, Hunan, China.
Zhibin
Z
Yu
Xiangya Nursing School, Central South University, Changsha, Hunan, China.
Jiarui
J
Chen
Pathology Department, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Xiaoling
X
She
Cancer Research Institute, School of Basic Medical Science, Central South University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Key Laboratory of Carcinogenesis, Ministry of Health, Changsha, Hunan, China.
Peiyao
P
Li
Cancer Research Institute, School of Basic Medical Science, Central South University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Key Laboratory of Carcinogenesis, Ministry of Health, Changsha, Hunan, China.
Changhong
C
Liu
Cancer Research Institute, School of Basic Medical Science, Central South University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Key Laboratory of Carcinogenesis, Ministry of Health, Changsha, Hunan, China.
Yan
Y
Zhang
Cancer Research Institute, School of Basic Medical Science, Central South University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Key Laboratory of Carcinogenesis, Ministry of Health, Changsha, Hunan, China.
Jianbo
J
Feng
Cancer Research Institute, School of Basic Medical Science, Central South University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Key Laboratory of Carcinogenesis, Ministry of Health, Changsha, Hunan, China.
Haijuan
H
Fu
Department of Spinal Surgery, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Bing
B
Wang
Department of Spinal Surgery, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Lei
L
Kuang
Department of Spinal Surgery, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Lei
L
Li
Department of Spinal Surgery, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Guohua
G
Lv
Cancer Research Institute, School of Basic Medical Science, Central South University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Key Laboratory of Carcinogenesis, Ministry of Health, Changsha, Hunan, China.
Minghua
M
Wu
D020413:3' Untranslated Regions / Q000235:genetics; D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism; D002470:Cell Survival / Q000187:drug effects / Q000235:genetics; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D035683:MicroRNAs / Q000235:genetics*; D009419:Nerve Tissue Proteins / Q000235:genetics / Q000378:metabolism; D012516:Osteosarcoma / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism; D011379:Prognosis; D055815:Young Adult
D020413:3' Untranslated Regions; D000970:Antineoplastic Agents; C503331:LRRC4 protein, human; C588249:MIRN381 microRNA, human; D035683:MicroRNAs; D009419:Nerve Tissue Proteins
LRRC4; chemosensitivity; miR-381; osteosarcoma